Introduction
Despite decades of research, the molecular mechanisms under lying major depressive disorder (MDD) remain poorly under stood, and current antidepressant treatments have many short comings. In the early 2000s, an initial report announced that a single intravenous infusion of ketamine at a subanesthetic dose had robust, rapid and sustained anti depressant effects in individuals with treatmentresistant depression (TRD). This exciting discovery has inspired tremendous interest over re cent years in investigating the mo lecu lar mechanisms mediat ing ketamine's clinical efficacy. This was accompanied by in creased efforts to identify new targets for antidepressant action, with a particular focus on the glutamatergic system. In this paper we review the clinical utility of ketamine and recent insights into its mechanism of action as an antidepressant, in cluding the roles of Nmethyld aspartate receptor (NMDAR) inhibition, αamino3hydroxy5methyl4isoxazolepropionic acid receptor (AMPAR) upregulation, activation of down stream synaptogenic signalling pathways (e.g., brainderived neurotrophic factor [BDNF] , mechanistic target of rapamycin [mTOR] ), as well as the production of an active ketamine metabolite (hydroxynorketamine [HNK] ). Emerging know ledge of the molecular mechanisms underlying ketamine's positive therapeutic and detrimental side effects will inform the development of a new generation of muchneeded su perior antidepressant agents.
Depression and current antidepressants
Depression is a prevalent and debilitating mental disorder that affects up to 350 million people globally and is associ ated with an extremely high personal and socioeconomic burden, with an estimated annual cost of $210 billion worldwide as a result of treatment expenditure and loss of productivity.
1,2 Current treatment options for people with MDD rely heavily on the use of antidepressant medications, most of which are monoaminergic agents, such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepres sants (TCAs), selective norepinephrine or dual serotoninnorepinephrine reuptake inhibitors and monoamine oxidase inhibitors (MAOIs). 3 The efficacy of these agents is based on the idea that monoamine neurotransmitter systems (pre dominantly serotonin, norepinephrine and dopamine) are hypoactive, especially in brain regions strongly implicated in the pathophysiology of MDD, such as the hippocampus and prefrontal cortex (PFC). [3] [4] [5] [6] Unfortunately, current anti depressants have several important shortcomings, including a delayed onset of therapeutic effects and limited efficacy. 7 Monoamine drugs are associated with a substantial time lag of several weeks to months before a therapeutic effect is ob served, which is a major concern, considering individuals with depression can be at high risk for suicide. 8, 9 In addition, clinical trials have reported that more than 60% of patients fail to obtain clinically important or sustained remission with a traditional antidepressant, with approximately one third of all depressed patients failing to respond to 2 or more firstline antidepressant treatments and thus being character ized as having treatmentresistant depression (TRD).
1,2 De spite decades of research, the fundamental neurochemical and molecular mechanisms underlying the disorder are still poorly understood, while current antidepressant treatments have limited clinical efficacy. This highlights a clear, unmet clinical need for safer, superior antidepressants with higher response rates and a more rapid onset of action.
Clinical efficacy and implications of ketamine
Owing to the therapeutic limitations of current antidepres sants as well as the lack of strong or direct evidence to sup port the monoamine deficiency hypothesis of depression, understandably there has been considerable and growing in terest in new targets for antidepressant action, with a particu lar focus on the glutamatergic system. 1, 9, 10 Ketamine hydro chloride is a noncompetitive, nonsubtype selective NMDAR antagonist, which has been used primarily as an anesthetic agent (at doses in the range of 1-3mg/kg) since the 1960s. 3 One of the most exciting discoveries in the field of depression treatment strategies came in 2000, when a seminal pilot trial first reported a rapid and robust antidepressant effect follow ing a single intravenous (IV) infusion of ketamine at a sub anesthetic dose in individuals with TRD. 11 Following this ini tial finding, several additional placebocontrolled randomized clinical trials and metaanalyses have been conducted, sup porting the utility of ketamine as a novel and potentially superior antidepressant. [12] [13] [14] Most of these trials used a single 40minute IV infusion of (R,S)ketamine (racemic mixture) at a dose of 0.5 mg/kg, resulting in response rates of 50%-70% in TRD populations. 1, 14, 15 Following a single infusion of ket amine, the majority of patients experienced considerable symptomatic relief (i.e., reductions in depressed mood, anhe donia and suicidal thoughts) as early as 2 hours after ket amine administration, with therapeutic effects peaking at 24 hours and lasting up to 2 weeks. 14, 16 Ketamine's rapid antidepressant effects are in stark contrast to the substantial delay in the onset of therapeutic effects fol lowing administration of traditional antidepressants. These rapid effects with an NMDA antagonist provide support for an alternative to the monoamine deficiency hypothesis of depres sion. Although monoaminergic systems do not appear to repre sent a convergent pathway regulating mood and mediating antidepressant response, emerging evidence suggests they may modulate downstream signalling pathways more directly tar geted by ketamine. 17 The duration of therapeutic effects initi ated by a single ketamine infusion, which can last up to 2 weeks, is maintained long after the complete metabolism and elimination of the drug (which has a plasma halflife of 2.5 hours). Accordingly, the sustained antidepressant response cannot be attributed to the direct receptor effects of ketamine, but instead may be mediated by activation of crucial down stream signalling cascades. 2, 12, 15 Not surprisingly, ketamine's unprecedented rapid and sustained antidepressant effects as well as its high response rates, especially in TRD populations, have inspired massive efforts to uncover the molecular mech anisms mediating the drug's unique therapeutic profile.
Despite these positive features, it is important to note that even at subanesthetic doses, ketamine administration is associated with mild and transient dissociative effects, neurocognitive and sensorimotor disturbances as well as short lasting elevations in heart rate and blood pressure. 2, 9 In addition, ketamine, or "Special K," is used as a recreational drug and thus has the potential to be abused, and prolonged use may cause neurotoxic effects. 1, 3 Hopefully, the identification of the mechanism of action underlying ketamine's anti depressant effects will assist in the development of novel rapid acting antidepressants that lack the features noted above that currently limit ketamine's wider clinical use.
Preclinical studies and insights into the mechanism of action of ketamine

Behavioural effects
These encouraging clinical findings of ketamine's utility in the treatment of depression inspired a wave of preclinical research designed to shed light on the molecular mech anisms underlying the robust antidepressant effects of ket amine. Numerous studies have successfully duplicated the positive effects of ketamine in rodent tests or models of de pression, including the forced swim test (FST; the most commonly used preclinical screen for antidepressant activ ity) and the chronic mild stress paradigm (CMS; the most commonly used preclinical model of depression). 18 A single systemic injection of ketamine at an intraperitoneal dose of 10mg/kg produces a significant reduction in FST immobil ity shortly (30 minutes to 1 hour) after administration, which has been shown to persist for an average of 7 days in both rats and mice. [19] [20] [21] [22] In addition, although rodents ex posed to chronic stress exhibit depressivelike behaviours, including despair/helplessness (as in the FST) and anhedo nia (as in the sucrose preference test [SPT]), ketamine is able to reverse these effects. 22, 23 In addition to mirroring the rapid and sustained anti depressant effects of ketamine seen in the clinic, animal studies have also yielded further intriguing observations. De spite the prevalence of MDD in women being roughly twice as high as in men, preclinical research investigating the mechanisms underlying ketamine's antidepressant effects has been conducted almost exclusively in male rodents.
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hand, there is also emerging evidence that repeated ket amine treatment (daily injections of 10 mg/kg for 21 days) effect ively sustains the antidepressant response in male mice, whereas it may actually worsen depression and anxiety related phenotypes in female mice. 25 Therefore, fur ther research into the sexspecific effects of ketamine is war ranted. It is also important to note that such preclinical studies involving prolonged expos ure to ketamine over sev eral days have also reported neurotoxicity in animal models of schizophrenia. 26 Thus, approaches that extend the thera peutic effects of ketamine without the onset of severe neuro toxicity and other side effects are much needed. In ad dition, whereas ketamine is usually administered as a race mic mixture, animal studies have shown that Sketamine is approximately 3-4 times more potent than Rketamine at indu cing both anesthesia and psycho tomimetic side ef fects. 27 Importantly, the Renantiomer is more effective than the Senantiomer at reducing depressiverelated behav iours, apparently without many of the side effects. 15, 22, 27 These findings highlight the potential of enantiomer specific therapy as a new approach for treating MDD.
Compelling clinical and preclinical evidence support ket amine's utility in treating depression and inspire many ef forts to uncover the molecular mechanisms responsible for ketamine's apparently superior antidepressant effects, which holds promise for a new generation of muchneeded, su peri or antidepressant agents.
Cellular and molecular effects
For almost 2 decades, the mechanisms mediating the anti depressant effects of ketamine were attributed to the direct inhibition of glutamatergic NMDA receptors. Until recently, the widely accepted model of ketamine's actions involved a cascade of events initiated by the preferential blockade of NMDA receptors located on γaminobutyric acid (GABA) ergic interneurons, whose tonic firing is driven by these NMDA receptors. 12 This in turn results in pyramidal cell dis inhibition and a surge of glutamate release, and subsequently in the activation of AMPA receptors along with release of BDNF and activation of downstream synaptogenic signalling pathways (e.g., mTOR).
12,28-30
Role of NMDA receptors
The promising clinical findings concerning ketamine's utility in treating depression prompted further investigation into the efficacy of other glutamatergic agents, with a particular focus on nonketamine NMDAR antagonists. 13 However, a growing body of evidence casts some doubt on the assump tion that ketamine's antidepressant effects are simply due to NMDAR blockade. First, as mentioned previously, R ketamine has more potent and sustained antidepressant properties than Sketamine in several rodent tests of depres sion. 22, 27 However, Sketamine is known to be approximately 4 times more potent than Rketamine at inhibiting NMDAR, which challenges the NMDAR hypothesis of ketamine ac tion. 22, 27, 31 Furthermore, animal studies indicate that treatment with the NMDAR antagonist MK801, which binds to the same receptor site as ketamine, failed to produce sustained antidepressant effects. 22, 29 Moreover, although the selective NMDA 2B blocker Ro25-6981 has antidepressant effects in rodents, these effects have been reported to be less robust and/or shorterlasting than ketamine. 23, 29, 32 In addition, more recent human clinical trials indicate that alternative NMDAR antagonists lack ketamine's robust, rapid and/or sustained antidepressant effects. 13, 22, 27 Also, in contrast to ketamine, other NMDAR antagonists, such as memantine, AZD6765 and CP101 606, have smaller effect sizes and produce shorterlasting symptomatic improvements. 13 Furthermore, 2 partial agonists at the NMDA glycine site, dcycloserine and rapastinel (GLYX13), appear to reduce depressive symptoms without clinically important psychotomimetic or dissociative side effects. 13, 27 However, to date, ketamine is the only NMDAR antagonist to consistently show antidepressant efficacy in multiple trials. Altogether, the hypothesis that NMDAR blockade is mainly responsible for the clinical effi cacy of ketamine appears to be effectively challenged. Clearly, further investigation is warranted in order to clarify the contribution of NMDAR blockade to ketamine's unique therapeutic profile and side effects.
Role of AMPA receptors
In contrast to the ambivalent findings concerning NMDAR inhibition, accumulating evidence supports the crucial in volvement of AMPA receptors in mediating the antidepres sant effects of ketamine. 16, 29, 33, 34 Studies in rodents show that ketamine produces a rapid and transient rise in glutamate re lease and cycling in the medial prefronal cortex (mPFC), which in turn leads to the acute activation of AMPA recep tors, properties proposed to mediate the rapid anti depressant effects of ketamine. 35, 36 Subanesthetic doses of ketamine facili tate AMPARmediated synaptic transmission in the mPFC, as shown by intracellular recordings of AMPA induced cur rents in rat mPFC pyramidal neurons 37 as well as in the hip pocampus, as measured by extracellular recordings and microiontophoresis of rat CA3 pyramidal neurons. 38 One study found that ketamine applied to hippocampal slices po tentiated CA1 AMPARmediated evoked neurotransmission within 30 minutes, which could not be attributed to increased presynaptic release probability. 39 Interestingly, when the same experiment was performed in GluA2 knockout mice, both the ketamineinduced synaptic potentiation and behav ioural antidepressant effects were absent. 39 Moreover, quanti tative electroencephalography (qEEG) performed in both humans and rodents within hours after ketamine administra tion has shown that this drug induces substantial increases in γband power, which depends on the activation of fast iono tropic excitatory receptors, mainly AMPARs. 22 In addition, ketamine treatment in rats can lead to upregulation of AMPAR subunit (GluA1 and GluA2) total or surface expres sion in the PFC and hippocampus, as measured by Western blot 22, 33, 40, 41 or by surface biotinylation assays, 39 along with in creased hippocampal AMPAR binding, as measured by auto radiography. 42 Interestingly, postmortem studies have re ported reductions in the mRNA expression levels of AMPA receptor subunits GluA1 and GluA3 in the perirhinal cortex, CA1 and dentate gyrus 44 of patients with depression, and several animal studies similarly found that exposure to chronic stress leads to a decrease in the expression of AMPAR subunits in these brain regions. [44] [45] [46] Sitespecific AMPAR phosphorylation at serine, threonine or tyrosine resi dues in the intracellular Cterminal domain by various protein kinases is known to modulate the channel kinetics, localization, subunit composition and protein-protein inter actions of AMPARs. 28 In addition to regulating the number of AMPA receptors on the surface, ketamine has been shown to affect the phosphorylation state of AMPAR subunits. How ever, conflicting reports show both increased 47 and de creased 29 phosphorylation of the GluA1 subunit at a key resi due (serine 845) in rodents hours after systemic injection of the drug, making it hard to draw any conclusions.
Importantly, several studies show that pretreating rats or mice with the AMPAR antagonist 2,3dihydroxy6nitro7 sulfamoylbenzo[f]quinoxaline2,3dione (NBQX) 10 minutes before ketamine injection blocks its rapid and sustained antidepressant effect in the FST without affecting other behaviours, such as the ketamineinduced hyper loco motion. 21, 22, 29, 33 Furthermore, NBQX administration 23.5 hours after ketamine treatment blocked its anti depressant effects in the FST at 24 hours. 22, 33 Interestingly, preclinical studies indicate that group II metabotropic glutamate (mGlu2/3) receptor antagonists, such as MGS0039 and LY341495, possess ketaminelike anti depressant effects, which can also be blocked by NBQX pretreatment and thus similarly involve AMPAR stimu lation. 33, 48 In addition, the SSRI fluoxetine and the TCA imipramine also are associated with upregulation of AMPARs in the hippocampus or mPFC, whereas their antidepressant action in the FST can be abolished by NBQX, indicating that facilitation of AMPARmediated signalling might represent a downstream point of convergence in the antidepressant action of ketamine and classical anti depressants. 45, 49 Taken together, these data indicate that activation of AMPA receptors, both at the time of injection and at later time points, is required for both the rapid and sustained antidepressant actions of ketamine.
Such findings encourage the investigation of drugs that en hance AMPAR function for their potential utility in treating depression. Preclinically, AMPARpositive allosteric modula tors (or AMPAkines, such as LY392098, LY451646 and Org 26576), 6, 28, 50, 51 the AMPAR agonist CX546 20 and AMPA itself 52 have dosedependent antidepressant activity in rodents and can enhance the effects of ketamine when coadministered as an adjunctive. In addition, the AMPAkine Org 26576 showed some (although not significant) efficacy, good tolerability and even cognitive enhancement in depressed patients in a small pilot phase 1b clinical trial, but further investigation of AMPAkines for depression is needed. 53 Therefore, conver gent evidence reveals that postsynaptic AMPA receptor acti vation and upregulation is emerging as a crucial factor in mediating ketamine's antidepressant effects 29 -findings that are particularly important at a time when the NMDA recep tor blockade hypothesis of ketamine's antidepressant actions is hotly debated.
Downstream signalling pathways, synaptic and structural plasticity
Consensus appears to be growing as to the key downstream cascades mediating ketamine's clinical efficacy. The most con sistent structural changes associated with MDD involve neur onal atrophy and brain volume loss in the hippocampus and PFC, 2 brain regions highly implicated in the patho physiology of depression and in mediating antidepressant responses. 10, 12, 54 These findings are supported by electrophysiological experi ments performed in rat hippocampal slices showing that acute stress causes an imbalance of synaptic plasticity favour ing longterm depression (LTD) over longterm potentiation (LTP), which in turn can lead to synaptic hypofunction, de stabilization and neuronal loss. 5, 55, 56 In fact, chronic stress is known to induce reductions in spine density and in the length and number of dendritic branches in the rat hippocampus and PFC. Importantly, all these dysfunctions in synaptic and structural plasticity can be reversed by ketamine. 23, 54 We con tend that the involvement of several neuroplasticityrelated processes acting synergistically to induce an upregulation of AMPARs and other synaptic proteins, accompanied by an in crease in synaptic strength and synaptogenesis, leading in turn to a rapid reversal of stress and depressioninduced neuronal dysfunction and atrophy, provide a compelling ar gument for a focus on AMPARs as a key to understanding the antidepressant actions of ketamine.
Chronic stress in animals and depression in humans are as sociated with decreases in the expression and/or function of BDNF in the PFC and hippocampus along with reports of lower BDNF blood levels in patients with MDD. 5, 9, 57, 58 On the other hand, many studies report that ketamine consistently causes an increase in BDNF translation and secretion in ro dents, again in the hippocampus and PFC, 2,20,30 although 1 study reported that ketamine's antidepressant efficacy was preserved in bdnf +/ heterozygous null mice. 51 In addition, BDNF is associated with antidepressant responses to classical antidepressants (e.g., SSRIs, TCAs), which lack efficacy in BDNF knockout mice. 2, 5, 57 Although it takes several weeks for these agents to trigger BDNFmediated synaptic plasticity, such changes can occur within hours following ketamine administration. 2, 5 Another key downstream convergence pathway impli cated in depression susceptibility and ketamine action is the mTOR signalling pathway, which regulates activity dependent synaptic plasticity and translation of synaptic pro teins. 41, 59 In addition, mTOR activation is accompanied by in hibition of eukaryotic elongation factor 2 (eEF2) kinase, desuppression of eEF2 and increased synaptic protein syn thesis (e.g., BDNF, GluA1-2, PSD95); promotes synapse for mation and maturation; and is believed to underlie the syn aptogenic effects of ketamine. 20, 41, 59 Consistent with this, both the antidepressant and synaptogenic effects of ketamine are blocked by preadministration of rapamycin, a selective mTOR inhibitor. 41 Importantly, mTOR activation is not seen following chronic treatment with any class of traditional anti depressant drugs. 5 Furthermore, consistent with the role of AMPAR in the ac tions of ketamine, the ketamineinduced increases in mTOR,
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BDNF and GluR1 levels can be prevented by pretreatment with the AMPA antagonist NBQX. 20, 29 Moreover, administra tion of AMPAkines appears to mimic these key molecular effects of ketamine and can be abolished by NBQX. 6, 20, 30, 33, 34, 48, 51, 52 Accumulating evidence indicates that ketamine enhances synaptogenesis and connectivity in the hippocampus, prefrontal cortex and associated regions via the activation of key signalling pathways, including those involving BDNF and mTOR. 5 At the level of neural circuits, both animal and human imaging studies suggest that by acti vating these signalling cascades, ketamine is able to effect ively reverse the loss of connectivity between the PFC and other limbic structures (e.g., amygdala) in depressed individ uals. Through these actions, ketamine appears to restore ap propriate top-down inhibitory control of hypothalamicpituitary-adrenal (HPA) axis reactivity, negative emotion and anxiety.
5,9
Ketamine metabolite
The latest piece of the ketamine puzzle was revealed in 2016 in a pivotal paper by Zanos and colleagues 22 published in Nature showing that an active ketamine metabolite exhibits similar efficacy without key receptor binding properties or side effects of its parent compound. 20 Ketamine is stereo selectively metabolized into a wide range of metabolites, many of which are presumed to be clinically inactive owing to the absence of anesthetic properties resulting from NMDAR antagonism. 31 Importantly, 1 ketamine metabolite, HNK, was observed to have 3fold higher brain concentra tions in female than in male rats, and this difference was postulated to underlie the enhanced potency of ketamine in females. 20, 22 Furthermore, this pivotal study showed that a metabolically inert form of ketamine with the same receptor binding properties but not metabolized into HNK lacked the sustained antidepressant actions of ketamine in several depressionrelevant tasks in rodents. 22 Interestingly, human data indicate a positive link between plasma HNK metab olite levels and antidepressant response to ketamine. 60 Next, Zanos and colleagues 22 showed that the HNK metabolite itself has robust rapid and sustained antidepressant action similar to ketamine, with (R,R)HNK being more potent than (S,S)HNK, mirroring the enantiomerspecific effects of the parent compound.
Similar to findings with ketamine, the AMPAR antagonist NBQX administered either before HNK injection or at the time of behavioural testing, blocked the rapid and sustained antidepressant effects of the metabolite. 22 Intriguingly, HNK does not bind to or functionally inhibit NMDARs, but instead causes a dramatic increase in AMPARmediated synaptic transmission in hippocampal CA1 slices, a rapid upregula tion of GluA1 and GluA2 AMPAR subunits in hippocampal synaptosomes (within an hour) and elevated levels of hippo campal BDNF (24 hours after treatment). 22 However, to date the mechanisms underlying the actions of ketamine or its metabolite on AMPARmediated transmission remain un clear. Importantly, Zanos and colleagues 22 did not evaluate the effects of HNK or ketamine on GluA1 and GluA2 phos phorylation, a process known to regulate channel trafficking and function, which limits any conclusion on the role of AMPAR in the effects of the ketamine metabolite. Finally, in contrast to ketamine, in preclinical tests HNK lacked sensory dissociation and hyperlocomotion effects, or reinforcing properties, and thus lacked the potential for abuse. 22 Overall, these exciting findings indicate that this key metab olite of ketamine is necessary and sufficient in rats for antidepressant actions of the prodrug. As HNK does not in hibit NMDARs, questions remain as to the molecular target responsible for its behavioural and synaptic effects. One re port claims that HNK can inhibit α7nicotinic acetylcholine receptor function (at concentrations of 1 μM), 31 but future studies are needed to define HNK's exact mechanism of action. In addition, although these findings with HNK repre sent important progress in the field, the claim that ket amine's clinical efficacy is exclusively due to an active me tabolite should be considered with caution. As ketamine is administered intraperitoneally in rats, it undergoes exten sive firstpass metabolism, so whereas the bioavailability of the parent compound can be as low as 20%, plasma and brain concentrations of its metabolites are relatively high. 12 In contrast, ketamine is administered clinically as an IV infu sion, thereby greatly reducing the firstpass liver metab olism, resulting in a different profile of ketamine/metabolite concentrations in the blood and central nervous system. Al though important questions remain as to whether or not HNK is exclusively responsible for ketamine's therapeutic actions, it is clear that it represents a new promising candi date antidepressant compound with an ability to modulate AMPAR function, which warrants further preclinical and clinical investigation.
Conclusion
A growing body of preclinical data challenges the prominent hypothesis that NMDA inhibition mediates the striking clin ical effects of ketamine in the treatment of depression. An emerging hypothesis proposes that ketamine has the unique ability to increase the AMPA-NMDA receptor throughput by directly blocking NMDA receptors and indirectly enhan cing AMPAR density and/or function, which in turn activates downstream synaptogenic signalling pathways (e.g., BDNF, mTOR) that restore synaptic strength and connectivity in the hippocampus and prefrontal cortex 12, 20, 28, 29 (see Fig. 1 for a con vergent model 61 ). Accordingly, we propose that future pre clinical and clinical research should focus on several promis ing avenues, including more direct enhancement of AMPAR function as a therapeutic strategy, enantiomerspecific ket amine therapy, the efficacy and mechanism of action of ket amine metabolites, repeated administration of optimized doses of ketamine to extend therapeutic effects without exa cerbating its side effects, and possibly combination therapy with ketamine and classical antidepressants. Importantly, there is every expectation that emerging knowledge of the molecular mechanisms underlying ketamine's therapeutic and side effects will inform the development of much needed new, superior antidepressant agents. The calcium influx and depolarization activates voltage-gated calcium channels (VDCCs). 5) The high local intracellular concentration of Ca 2+ triggers the activity-dependent vesicular release of brain-derived neurotrophic factor (BDNF) into the synaptic space. 6) BDNF binds to and activates its surface receptor, tropomyosin receptor kinase B (TrkB), which activates 2 major downstream signalling cascades involving MEK-ERK and PI3K-Akt. These 2 pathways converge onto the mechanistic target of rapamycin (mTOR), which is a key regulator of protein synthesis and synaptic plasticity. 7) These events lead to disinhibition of synaptic protein translation (e.g., GluR1-2, PSD95, synapsin1) as well as BDNF, in part through the supressed phosphorylation of eukaryotic elongation factor 2 (eEF2). 8) These newly synthesized proteins are then inserted into the postsynaptic density, leading to further increases in AMPAR-mediated synaptic transmission and dendritic spine density, thus causing massive synaptogenesis. This series of events is believed to restore normal connectivity between key brain regions, such as the PFC and limbic structures like the hippocampus and amygdala. The AMPAR antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) completely abolishes ketamine's antidepressant actions, supporting the role of AMPA receptors in mediating these effects. On the other hand, AMPA potentiating agents could represent a more targeted strategy of obtaining ketamine-like antidepressant effects. The ketamine metabolite, hydroxynorketamine (HNK), has been recently shown to facilitate AMPAR-mediated transmission, but the exact molecular target and mechanism of action of HNK remain unknown. Figure adapted with permission from from Sanacora and Schatzberg. 61 JPN Commentaries are an article type similar to reviews, but are designed to make a point about a topic without reviewing the topic comprehensively.
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